Expert perspectives on cholangiocarcinoma (CCA)

Overview of CCA (ILCA 2020)

Professor Bruno Sangro

Director, Liver Unit & Co-Director, HPB Oncology Area, Clinica Universidad de Navarra, Pamplona, Spain

Unmet needs in CCA (ESMO 2020)

Helen Morement

CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK

Importance of the multidisciplinary team in CCA diagnosis and treatment (ESMO 2020)

Professor Lorenza Rimassa

Associate Professor of Medical Oncology, Humanitas University and Humanitas Research Hospital-IRCCS, Milan, Italy

Helen Morement

CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK

Professor Juan Valle

The Christie NHS Foundation Trust and
University of Manchester, UK

Professor Peter Schirmacher

Institute of Pathology, University Hospital Heidelberg

Importance of performing biopsies in patients with CCA (ESMO 2020)

Professor Lorenza Rimassa

Associate Professor of Medical Oncology, Humanitas University and Humanitas Research Hospital-IRCCS, Milan, Italy

Helen Morement

CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK

Professor Juan Valle

The Christie NHS Foundation Trust and
University of Manchester, UK

Professor Peter Schirmacher

Institute of Pathology, University Hospital Heidelberg

Importance of molecular profiling in patients with CCA (ESMO 2020)

Professor Lorenza Rimassa

Associate Professor of Medical Oncology, Humanitas University and Humanitas Research Hospital-IRCCS, Milan, Italy

Helen Morement

CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK

Professor Juan Valle

The Christie NHS Foundation Trust and
University of Manchester, UK

Professor Peter Schirmacher

Institute of Pathology, University Hospital Heidelberg

Detecting FGFR2 fusions in patients with CCA (ESMO GI 2021)

Dr Nicola Normanno

Istituto Nazionale per lo Studio e la Cura dei Tumori. Fondazione G. Pascale, Italy

Importance of biomarkers in CCA (ESMO GI 2021)

Dr Angela Lamarca

Fundación Jiménez Díaz University Hospital, Spain

When could “cancer of unknown primary” be CCA? (ESMO 2021)

Professor Juan Valle

The Christie NHS Foundation Trust and
University of Manchester, UK

Optimising the multidisciplinary team for CCA management (ESMO 2021)

Dr David Malka

Institut Mutuaslite Montsouris, France

Company/Organisation	Relationship(s)
Adaptimmune, AstraZeneca, Bayer, Bristol Myers Squibb, Boston Scientific, Eisai, Exelixis, Ipsen, Lilly, Merck, Novartis, Roche, Sirtex Medical, Terumo	Consulting, advisory role or honoraria
Bristol Myers Squibb, Sirtex Medical	Grants

Company/Organisation	Relationship(s)
Amgen, ArQule, AstraZeneca, Basilea, Bayer, Celgene, Eisai, Exelixis, Hengrui, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Nerviano Medical Sciences, Roche, Sanofi	Consulting/Advisory role
AbbVie, Amgen, Eisai, Gilead, Incyte, Ipsen, Lilly, Roche, Sanofi	Honoraria/Lectures
Ipsen	Travel expenses
Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Roche	Research funding to institution

Company/Organisation	Relationship(s)
Imaging Equipment Ltd, Ipsen, Novartis, NuCana	Speakers bureau
Celgene, NuCana	Travel Grant
Agios, AstraZeneca, Debiopharm, Delcath Systems, GenoScience Pharma, Imaging Equipment Ltd, Incyte, Ipsen, Keocyt, Merck, Mundipharma EDO, Novartis, NuCana, PCI Biotech, Pieris Pharmaceuticals, Pfizer, QED, Servier, Wren Laboratories	Grant support

Company/Organisation	Relationship(s)
AstraZeneca, Incyte, Janssen, Novartis, Roche	Speakers bureau
Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Incyte, Janssen, Merck Sharp & Dohme, Novartis, Roche	Board
AstraZeneca, Bristol Myers Squibb, Illumina, Novartis	Grant support

Company/Organisation	Relationship(s)
Amgen, ArQule, AstraZeneca, Basilea, Bayer, Celgene, Eisai, Exelixis, Hengrui, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Nerviano Medical Sciences, Roche, Sanofi	Consulting/Advisory role
AbbVie, Amgen, Eisai, Gilead, Incyte, Ipsen, Lilly, Roche, Sanofi	Honoraria/Lectures
Ipsen	Travel expenses
Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Roche	Research funding to institution

Expert perspectives on cholangiocarcinoma (CCA)

Overview of CCA (ILCA 2020)

Unmet needs in CCA (ESMO 2020)

Importance of the multidisciplinary team in CCA diagnosis and treatment (ESMO 2020)

Importance of performing biopsies in patients with CCA (ESMO 2020)

Importance of molecular profiling in patients with CCA (ESMO 2020)

Detecting FGFR2 fusions in patients with CCA (ESMO GI 2021)

Importance of biomarkers in CCA (ESMO GI 2021)

When could “cancer of unknown primary” be CCA? (ESMO 2021)

Optimising the multidisciplinary team for CCA management (ESMO 2021)

All videos in this category

Overview of CCA (ILCA 2020)

Unmet needs in CCA (ESMO 2020)

Importance of the multidisciplinary team in CCA diagnosis and treatment (ESMO 2020)

Importance of performing biopsies in patients with CCA (ESMO 2020)

Importance of molecular profiling in patients with CCA (ESMO 2020)

Detecting FGFR2 fusions in patients with CCA (ESMO GI 2021)

Importance of biomarkers in CCA (ESMO GI 2021)

When could “cancer of unknown primary” be CCA? (ESMO 2021)

Optimising the multidisciplinary team for CCA management (ESMO 2021)

Enhance your CCA knowledge with Incyteful

Company/Organisation	Relationship(s)
MSD, Qiagen, Bayer, Biocartis, Illumina, Incyte, Roche, BMS, Merck, Thermo Fisher, Boehringer Ingelheim, AstraZeneca, Sanofi, Eli Lilly	Personal financial interests (speaker’s fee and/or advisory boards)
Merck, Sysmex, Thermo Fisher, QIAGEN, Roche, AstraZeneca, Biocartis, Illumina	Institutional financial interests (financial support to research projects)
President, International Quality Network for Pathology (IQN Path); President, Italian Cancer Society (SIC)	Non-financial interests

Company/Organisation	Relationship(s)
Albireo Pharma, AstraZeneca, Boston Scientific, EISAI, Ipsen, QED, Nutricia, Roche, Servier	Consulting honoraria
AAA pharmaceuticals, AstraZeneca, EISAI, Incyte, Ipsen, QED, Merck, Pfizer, Servier	Speaker honoraria
AAA pharmaceutical, Bayer, Delcath Systems, Ipsen, Mylan, Novartis, Pfizer, Sirtex Medical	Travel, education funding